Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25325573 | 1.00 | CNR1 (0.37) | CNR1 | |
| SCHEMBL22100789 | 0.81 | NPC1 (0.40) | CNR1 | |
| SCHEMBL25327181 | 0.81 | ALOX5 (0.31) | — | |
| SCHEMBL25327183 | 0.81 | ALOX5 (0.31) | — | |
| SCHEMBL28466856 | 0.81 | NPC1 (0.40) | CNR1 | |
| SCHEMBL28466853 | 0.81 | NPC1 (0.40) | CNR1 | |
| SCHEMBL1231564 | 0.78 | SERPINH1 (0.39) | CNR1 | |
| SCHEMBL19925886 | 0.78 | CTSS (0.33) | — | |
| SCHEMBL19925884 | 0.78 | CTSS (0.33) | — | |
| SCHEMBL19926161 | 0.78 | CTSS (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4469445-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282749-A1 | COMPOUNDS AND METHODS OF USE | CYP1B1, CYP2C19, UGT1A1 | CNR1 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.